Sofinnova Investments’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Sofinnova Investments’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-981,928	Closed	-$2.98M	–	68
2022 Q2	$2.98M	Sell	981,928 -499,291	-34%	-$2.43M	0.25%	48
2022 Q1	$10.1M	Sell	1,481,219 -101,558	-6%	-$724K	0.76%	31
2021 Q4	$13.2M	Buy	1,582,777 +945,430	+148%	+$7.79M	0.77%	36
2021 Q3	$4.74M	Buy	637,347 +12,591	+2%	+$78K	0.28%	57
2021 Q2	$4.25M	Buy	624,756 +112,934	+22%	+$938K	0.24%	54
2021 Q1	$5.26M	Sell	511,822 -413,458	-45%	-$4.53M	0.32%	48
2020 Q4	$6.48M	Buy	+925,280	New	+$7.2M	0.39%	44

Other funds holding JNCE

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Sofinnova Investments's JNCE Position: Q3 2022 in Review

Sofinnova Investments sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2022, closing a stake of 981,928 shares — an estimated $2.98M sold.

Sofinnova Investments first reported a position in JNCE in Q4 2020 and held it in 7 quarters. The position peaked at $13.2M in Q4 2021. 102 funds tracked by Wall St. Rank hold JNCE as of Q3 2022.

Sofinnova Investments reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Sofinnova Investments sold 981,928 Jounce Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $2.98M.
Sofinnova Investments first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
Sofinnova Investments's Jounce Therapeutics, Inc. Common Stock position peaked at $13.2M in Q4 2021.
102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Sofinnova Investments's 13F filing for Q3 2022, filed 8 Nov 2022.